Compare INHD & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INHD | XBIO |
|---|---|---|
| Founded | 2019 | N/A |
| Country | Hong Kong | United States |
| Employees | N/A | 2 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 8.2M |
| IPO Year | 2023 | N/A |
| Metric | INHD | XBIO |
|---|---|---|
| Price | $0.18 | $3.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 14.6M | 15.0K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.61 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,846,250.00 | N/A |
| Revenue This Year | N/A | $2.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 221.43 | N/A |
| 52 Week Low | $0.06 | $1.90 |
| 52 Week High | $15.90 | $13.93 |
| Indicator | INHD | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 19.21 | 54.38 |
| Support Level | $0.09 | $2.70 |
| Resistance Level | $1.25 | $3.60 |
| Average True Range (ATR) | 0.16 | 0.21 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 0.95 | 51.03 |
Inno Holdings Inc is a building technology company with a mission to transform the construction industry with its proprietary cold-formed steel-framing technology and other innovations. It is a manufacturer of cold-formed-steel members and prefabricated homes. It offers a full range of services required to transform raw materials into precise steel framing products and prefabricated homes. The company sells these finished products either to businesses or directly to customers. The finished products and cold-formed-steel members are used in a variety of building types, including residential, commercial, industrial and infrastructure.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.